Explore Stanford technologies available for licensing:

Stanford scientists have developed a neuroprotective, adeno-associated virus (AAV) gene therapy vector that expresses a mutant form of HDAC4 or a fragment of HDAC4 with novel applications to retinal and neurologic diseases, including glaucoma and other retinal ganglion cell di

Researchers at Stanford have developed a tunable proximity assay with a wide dynamic range that can detect multiple analytes in a single sample.

Stanford researchers from the Khuri-Yakub group have designed an improved, high spatial resolution ultrasonic neuromodulation device that implements chip waveform instead of continuous wave PIRF.

Researchers at Stanford have demonstrated the first method of its kind for treating cystic fibrosis (CF) using regenerated airway stem cells embedded on a biocompatible scaffold.

Stanford researchers developed a novel bioprinting platform for fabricating human assembloids with spatial control of organoid fusion.

Stanford researchers developed a new technology that prints networks with distinct branch structures that emulate the natural branching observed in in vivo vascular networks.

Stanford inventors have developed a multiomic methodology for identifying and measuring non-structural proteins and RNA species from human hair. This approach will reveal unique biomarker profiles for wellness or diseases that are not currently identified.

Prematurity is the single largest cause of death in children under 5 years of age, both in low-and high-income countries.

Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.

Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.

Stanford inventors have engineered an adeno-associated virus (AAV) variant on the existing LK03 platform that enables this highly efficient primate-specific serotype for use in rodent preclinical studies.

Researchers at Stanford have developed a potentially curative treatment strategy for alpha-thalassemia, one of the most common autosomal recessive disorders in the world involving the genes HBA1 and/or HBA2.

Stanford researchers developed a technology that efficiently identifies combinations of genetic interventions with lasting, effective therapeutic functions by constructing genetic perturbation libraries containing the desired combination of phenotypes extracted from each cell.

Stanford researchers have developed method for targeted application focused ultrasound to peripheral nerves to suppress acute pain.

Stanford inventors have engineered a therapy (PEN-SP9) that blocks rapid mucin secretion without impairing lung health.